We use cookies to make your experience better. To comply with the new e-Privacy directive, we need to ask for your consent to set the cookies. Learn about our cookie policy.
Cayman Glipizide-d11
Product Description
Glipizide-d11 is intended for use as an internal standard for the quantification of glipizide (Item No. ) by GC- or LC-MS. Glipizide is a hypoglycemic agent. It inhibits ATP-sensitive potassium (KATP) channels in primary mouse pancreatic β cells (IC50 = 6.4 nM). Glipizide induces insulin release from isolated rat pancreatic tissue with an EC50 value of 40 nM. Dietary administration of glipizide (5 mg/kg per day for 10 days) increases the number of insulin receptors on isolated and purified mouse liver plasma membranes. It reduces plasma glucose and triglyceride, but not total cholesterol, levels and increases plasma insulin levels in a rat model of diabetes induced by a high-fat diet and streptozotocin (STZ; Item No. ) when administered orally at a dose of 5 mg/kg. Formulations containing glipizide have been used in the treatment of type 2 diabetes.
WARNING This product is not for human or veterinary use.
Technical Information
- CP 28720
- K 4024
- TK 1320
- DMSO: Slightly soluble
- Ethyl Acetate: Slightly soluble
Shipping & Storage Information
| SKU | CAYM-30074-500 |
|---|---|
| Supplier Part Number | 30074-500 |
| UM | EA |
| UNSPSC | 12352200 |
| Manufacturer | Cayman |
| MSDS URL | Click here |
| Temperature | -20 |
| Refrigerated-Frozen | Y |
| CountryOfOrigin | Canada |
| ProductLine | CAYM |
| Qty | 1 |
| MinOrderQty | 1 |
| Weight | 7.000000 |
| Lead Time | 5 |
| Hazardous | N |
| CAS Number | 1189426-07-0 |
| Energy Star | No |
| Green | No |
| Controlled | N |